Late Breaking Abstract - Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival

Background: Thoracic cancer patients (pts)s are emerging as a particularly frail population in the ongoing COVID-19 pandemic. This can be linked to older age, preexisting comorbidities, smoking, and pre-existing lung damage as predisposing factors. Method: TERAVOLT is an international longitudinal survey of consecutive pts with thoracic malignancies and COVID-19 infection. Goals are to collect data for guidance on treatment while understanding the risk factors for morbidity and mortality. Gray’s test was used for comparing Cumulative Incidence among levels of potential risk factors. Results: We report here on 400 pts from 29 centers. Median age was 65 years, male 66%, 72% current/former smokers, hypertension (53%) and COPD (31.2%) as most common comorbidities; Median follow-up was 33 days. Age >65 (p=0.0033), presence of comorbidities (p=0.035) and ECOG PS ( Conclusion: These data suggest that pts with thoracic malignancies have a high COVID-19 mortality. Particular attention should be paid to pts> 65 years of age, with comorbidities, particularly if they are receiving chemotherapy.